• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biotechnology in India - Global Business Strategic Report Product Image

Biotechnology in India - Global Business Strategic Report

  • Published: May 2012
  • Region: Global, India
  • 396 Pages
  • Global Industry Analysts, Inc

This report analyzes the market for Biotechnology in India in US$ million by the following Key Sectors: Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 102 companies including many key and niche players such as Advanced Enzymes Technologies Ltd., Ajeet Seeds Ltd., Anthem BioSciences Pvt. Ltd., Bharat Biotech International Limited, Bharat Serums and Vaccines Ltd., Biocon Limited, Syngene International Limited, Dr. Reddys Laboratories Ltd., Ecron Acunova, Eli Lilly and Company (India) Pvt. Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Indian Immunologicals Ltd., Jubilant Life Sciences Limited, Krishidhan Seeds Private Limited, Lambda Therapeutic Research Ltd., Mahyco, Max Neeman, Monsanto, Novo Nordisk India Pvt. Ltd., Novozymes South Asia Pvt. Ltd., Nuziveedu Seeds Pvt. Ltd., Ocimum Biosolutions Ltd., Panacea Biotec Ltd., Piramal Healthcare Limited, Quintiles India, Rasi Seeds (P) Ltd., Reliance Life Sciences, Serum Institute of India Ltd., Shantha Biotechnics Limited, SIRO Clinpharm, Strand READ MORE >

BIOTECHNOLOGY IN INDIA

AN INDIAN MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definition and Scope of Study I-3
Bio-Pharmaceuticals I-3
Bio-Agriculture I-3
Bio-Industrial I-3
Bioinformatics I-3
Bio-Services I-3

II. AN INDIAN MARKET REPORT

1. OUTLOOK II-1
Recession and Foreign Exchange Rate Decelerate Industry Growth II-1
Industry Emerges Strong Following Recession II-2
Brighter Prospects Ahead for the Indian Biotech Industry II-2

2. INDUSTRY OVERVIEW II-3
SWOT Analysis II-3
Diversity - Key Strength for the Industry II-4
Major Sectors in the Indian Biotechnology Industry II-4
Government Support for Biotech Innovation - A Boost for the
Industry II-5
Challenges Ahead II-5
Concerted Efforts are On to Find a Way Out II-6
Major Industry-Specific Advantages of the Indian Biopharma Sector II-6
Competition II-7
Table 1: Leading Biotech Companies in India by Revenues:
2009-10 (includes corresponding Graph/Chart) II-7

Table 2: Leading Domestic Biotech Companies in India by
Revenues: 2009-10 (includes corresponding Graph/Chart) II-8
Exports - A Major Market for Indian Biotech Industry II-8
Table 3: Export Revenues of Indian Biotech Industry by Sector
(2008-09 & 2009-10): Export Value in US$ Million for
Bio-Pharma, Bio-Services, Bio-Agri, Bio-Industrial, and
Bioinformatics (includes corresponding Graph/Chart) II-9

Table 4: Biotechnology Industry Export Revenues as a
Percentage Share of Total Segment Revenues: 2009-10 (includes
corresponding Graph/Chart) II-9
Analysis by Region II-10
Western Region’s Domination Continues in Revenue Terms,
Mumbai Moves to the Top II-10
Table 5: Leading States in the Indian Biotech Industry by
Revenues: 2009-10 (includes corresponding Graph/Chart) II-10

Table 6: Leading Cities In the Indian Biotech Industry by
Revenues: 2009-10 (includes corresponding Graph/Chart) II-11
Karnataka Embarks on Further Growth Plans
Other Regions Join
the League II-11

3. ISSUES AND TRENDS II-13
Government Support to the Biotechnology Sector Surges II-13
Recognizing the Importance of Right Educational System II-13
Need for a Streamlined Regulatory Process Continues II-14
Angel Funding - Still Eluding the Sector II-14
More Countries Look to India for Outsourcing II-14
China and India - Competing for Biotech Investments II-15

4. BIO-PHARMACEUTICALS IN INDIA II-16
Table 7: Indian Bio-Pharmaceuticals Market by Segment (2011):
Percentage Share Breakdown for Vaccines, Diagnostics,
Therapeutics, and Others (includes corresponding Graph/Chart) II-16
Competitive Landscape of the Biopharma Sector II-17
Table 8: Leading BioPharma Companies in India by Revenues:
2009-10 (includes corresponding Graph/Chart) II-17
Market Analysis by Segment II-18
Vaccines II-18
Vaccines to Spearhead Growth in the Indian BioPharma Market II-18
Demand for Vaccines to Surge II-18
India to Emerge as a Global Hub for Vaccines II-19
Diagnostics II-19
India Diagnostics Market - An Overview II-19
Table 9: Leading Players in the Indian Diagnostics Market
by Revenues: Market Share Breakdown of Revenues for Tulip,
TransAsia Biomedical, Bayer, Span Diagnostics, and Others
(2010) (includes corresponding Graph/Chart) II-19
Indian Diagnostics Industry - Stifled with High Competition II-20
Diagnostic Centers Expand Test Menu to Beat Competition II-20
Bio-Therapeutics - Going Strong II-20
Overseas Giants Dominate the Insulin Market II-20
Plasma Proteins - A Potential Growth Area II-21
mAbs Gain Prominence in the Biopharma Industry II-21
Market Trends II-22
Climbing Up the Value Chain II-22
Domestic Market to Provide Impetus to Bio-Pharma Industry Growth II-22
Biosimilars to Offer Tremendous Prospects for Indian Players II-23
Table 10: Indian Market for Biosimilars by Drug Class
(2009): Revenues for Insulin, EPO, Interferon,
Streptokinase, and G-CSF (includes corresponding
Graph/Chart) II-23
Biopharmaceutical Pipeline Growth Continues II-23
r-DNA Biopharmaceuticals Cleared for Pre-Clinical Studies:
2009-10 II-24
Indian Firms Embrace Strategic Partnerships to Enter Biotech
Industry II-25
Indian Biopharma Market Luring Overseas Players II-25
Indian Pharma Companies on a Co-Development Spree II-26
Vaccines Remain the Center of Focus in Indian BioPharma II-27
Brighter Prospects Ahead in Original Drug Development II-27
Myriad Factors Drive Growth in the Indian BioPharma Sector II-28
Pharma Companies Shift Focus to BioPharma II-28

5. BIO-AGRICULTURE IN INDIA II-29
Indian Bio-Agriculture Industry - An Overview II-29
Select Biotech Crops in India Under Field Trials: 2008 II-30
Transgenic Crops Cleared for Limited Field Trials: 2009-10 II-31
India - A Leading Adopter of Biotech Crops Worldwide II-31
Bio-Agri Treads On A Fast-Track Growth Path II-31
Public and Private Sector Participation in Bio-Agri Research II-32
Bt Cotton - A Major Success in India II-32
Indian Farmers Increasingly Embrace Bollgard II Cotton II-33
Monsanto And Mahyco to Battle Out Pink Bollworm Resistance in
Bollgard - I II-33
Move to Commercialize Bt Brinjal Draws Major Controversy II-33
Government Retreats, Imposes Moratorium on Launch of Bt Brinjal II-34
Moratorium on Bt Brinjal Launch, A Setback to the Industry? II-34
Establishment of BRAI Also Faces the Heat of Opponents II-35
Stark Criticism Compels India to Establish Transparent
Administration of Biotech Procedures II-35
Bio-Diesel Market - Still in Infancy II-36
Bio-Fertilizers and Bio-Pesticides Market - An Overview II-36
Competitive Scenario in the Bio-Agri Sector II-37
Table 11: Leading Bio-Agriculture Companies in India by
Revenues: 2009-10 (includes corresponding Graph/Chart) II-37

6. BIO-INDUSTRIAL SECTOR IN INDIA II-38
Indian Bio-Industrial Sector - Fairly Concentrated II-38
Table 12: Leading Players in the Indian Bio-Industrial Sector
(2009-10): Market Share as Percentage of Revenues for
Novozymes, Advanced Enzyme Technologies, and Others (includes
corresponding Graph/Chart) II-38

7. BIOINFORMATICS II-39
Indian BioInformatics Market Posts Sluggish Growth II-39

8. BIO-SERVICES II-40
Indian Bio-Services Market Bustling with Activity II-40
India - A Growing Hub for Clinical Trials II-40
Competitive Scenario II-41
Table 13: Leading Biotechnology Services Companies in India
By Revenues (2009-10) (includes corresponding Graph/Chart) II-41

9. REGULATORY SETUP II-42
Regulatory Evolution in the Country II-42
Department of Biotechnology II-42
Public Sector Undertakings under the DBT II-42
Autonomous Institutions operating under the DBT II-42
Roles and Responsibilities of DBT II-43
Various Committees Operating Under the DBT and MoEF II-43
GEAC or the Genetic Engineering Approval Committee II-43
Review Committee on Genetic Manipulation II-43
Institutional Bio-Safety Committee II-43
Recombinant DNA Advisory Committee II-44
Central Drugs Standard Control Organization II-44
Select Acts, guidelines and regulations that govern the
biotechnology industry in India II-44
Agencies Supporting and Financing Biotechnology Research in
India II-45
New Regulatory Framework on the Horizon II-45
National Biotechnology Strategy II-45

10. INDUSTRY INFRASTRUCTURE II-46
Biotech and Science Parks in the Country II-46
Select Biotech and Science Parks in India II-46
Major Research Institutes in India II-46
Select Key Research Institutes in India II-46
Autonomous Biotechnology Institutes in India II-47

11. BIOTECHNOLOGY - AN OVERVIEW II-48
Biotechnology II-48
A Peek into the History of Biotechnology II-48
Select Major Applications of Biotechnology II-48
Medicine II-49
Pharmacogenomics II-49
Biopharmaceuticals II-49
Genetic Testing II-49
Gene Therapy II-50
Cloning II-50
Agriculture II-50
Bioremediation and Biodegradation II-50

12. PRODUCT APPROVALS/LAUNCHES II-51
Panacea Biotec to Introduce PacliALL II-51
Gene Logic Rolls Out ASCENTA System Version 4.0 II-51
Bharat Biotech International Unveils HNVAC™ H1N1 Swine Flu
Vaccine II-51
Strand Scientific Intelligence Introduces Avadis NGS II-52
Dr Reddy’s Rolls Out Generic Darbepoetin Alfa Drug, Cresp® II-52
BD Biosciences and ReaMetrix Unveil New Reagents II-52
Serum Institute of India Rolls Out Nasovac H1N1 Vacccine in India II-52
Ocimum Biosolutions Introduces Biotracker™ II-53
Novo Nordisk Launches Antidiabetic Drug, Victoza in India II-53
Cadila Healthcare Launches Vaxiflu-S II-53
Ocimum Biosolutions Introduces qRT-PCR Services II-54
Wockhardt Rolls Out Biotechnology Products II-54
Intas Biopharma Launches Borviz in India II-54
Bharat Biotech International Unveils COMVAC5® Vaccine II-54

13. RECENT INDUSTRY ACTIVITY II-55
Piramal Healthcare to Change Name to Piramal Enterprises II-55
Bharat Biotech Commences Phase III Clinical Trial with THR-100 II-55
Bayer Teams Up with Zydus for Joint Venture in India II-55
Qiagen Establishes Qiagen India II-56
Ecron Acunova Expands Capacity at Mangalore Clinical Research
Center II-56
IndianOil Inks MOU with LanzaTech II-56
Dow AgroSciences and GVK Biosciences Discover New Compound II-56
Ecron Acunova Establishes Joint Venture CRO in Thailand II-57
Praj Industries Enters into Partnership with Qteros II-57
Mavens Biotech to Venture into Biotech Education II-58
Aurobindo Pharma to Divest Stake in Its Chinese Subsidiary II-58
Abbott Acquires Formulation Business of Piramal Healthcare II-58
Evolvence India Life Sciences Takes Over Stake in Fermenta Biotech II-58
Strides Arcolab to Take Over 70% Stake in Inbiopro Solutions II-59
Rallis Acquires Majority Stake in Metahelix II-59
Ocimum Secures US$8 Million Funding for Future Growth II-59
Dr. Reddys to Purchase US Penicillin Facility and Product
Rights from GSK II-59
Life Technologies to Take Over Labindia II-60
Biocon Enters into Strategic Global Agreement with Pfizer II-60
Intas Biopharma to Ink Out-Licensing Deal with Japanese Firm II-60
Biocon Limited and CMI Enter into Immunology Research
Collaboration II-61
Biocon Signs Contract with Teleradiology Solutions II-61
Jubilant Organosys Changes Name to Jubilant Life Sciences II-61
Jubilant Inks CRAMS Deal with a US Firm II-61
MSCCC and Strand Life Sciences Ink MOU for Translational
Cancer Research II-62
Lohmann Animal Health Enters into Joint Venture with Suguna II-62
International Stem Cell Inks a Distribution Agreement with
Sristi Biosciences II-62
BioServe Biotechnologies Receives NABL Accreditation for GMO
Testing II-63
Indian Immunologicals to Develop Oral Cervical Cancer Vaccine II-63
Piramal Healthcare to Take Over the Assets of BioSyntech II-63
Ocimum Biosolutions to Offer BioIT Consulting Services II-63
Zydus Obtains DCGI Clearance for Initiating Phase I Trials on
Zyog1 II-64
Krishidhan Establishes Subsidiary in Europe II-64
Biocon Limited Inks Supply Deal with Optimer Pharmaceuticals II-64
Australia to Grant Research Funding to India II-64
Ocimum Biosolutions and Jivan Biologics Enter into Partnership II-65
Stempeutics Completes Phase I/II Study of Stemepucel-CLI Stem
Cell Product II-65
Ranbaxy Enters into Alliance with Pfenex II-65
Syngene Collaborates with Endo Pharmaceuticals II-65
Panacea Biotech Obtains Financial Assistance from DBT for
Vaccine Development II-66
M. D. Anderson Cancer Center Selects Biotracker™ of Ocimum
Biosolutions II-66
GVK Biosciences Establishes New Clinical Pharmacology Unit II-66
Delta Embedded Solutions to merge with Bio-Analytical
Technologies II-67
Clingene Seeks Alliance with SIRO Clinpharm II-67
Biocon Investments in Malaysian Biotech Market II-67
Ranbaxy to Foray into Vaccines Market through Acquisition of
Biovels Assets II-68
Clinigene International Deploys PheedIt Solution of SAS II-68
Sanofi Takes Over Shantha Biotech II-68
Bioseed Research India Inks Strategic Partnership Agreement
with KeyGene II-69
PRAJ Partners with Novozymes II-69
Mylan sells stake in Concord Biotech II-69
Vibha Seeds Sets Up Seed Facility in Andhra Pradesh II-69
Bayer Cropscience Inks Research Cooperation Agreement with GVK
Biosciences II-70
Millipore Acquires Outstanding Stake of its Joint Venture in
India II-70
Avesthagen Forms Joint Venture with Limagrain II-70
Indus Biotech Receives HIV Controller Status for IND02 from FDA II-70
Bharat Biotech Commences Construction at Konark Knowledge Park
in Orissa II-71
International Biotech Park to Forge International Alliances II-71
Merck Acquires Bangalore Genei II-71
Bharat Biotech Secures International Patents for Lysostaphin II-71
Genzyme Inks MoU with NIPER for Offering Biotechnology
Fellowships II-72
Biocon Enters into Agreement with Amylin Pharmaceuticals II-72
WHO and DCGI Direct Serum Institute of India to Focus on H1N1
Vaccine II-72
Acoris Research Enters into Strategic Partnership with c-LEcta II-72
Serum Institute of India to Expedite Vaccine Development II-73
Sanofi Aventis Acquires Shantha Biotechnics II-73
Biocon Inks a Strategic Collaboration Agreement with Mylan II-73
Lonza to Invest in Genome Valley for Two Major Projects II-73
Bio-Rad Laboratories Integrates DiaMed Scientific Technologies
in India II-74
Syngene Enters into Alliance with DuPont Crop Protection II-74
Emami Biotech Limited and Calcutta Tramways Company Ink MoU II-75
TCG Lifesciences and Pfizer Extend Master Services Agreement II-75
Biological E Commences Operations at New Campus II-75
Syngene Enters into Partnership with Sapient II-75
Intas Biopharmaceuticals Inks MoU with Government of Gujarat II-76
Emami’s Bio-Diesel Obtains SGS Certification II-76
Ocimum Biosolutions Enters into Partnership with NuGEN II-77

14. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-78
Biocon Collaborates with Abraxis to Introduce Abraxane in India II-78
Intas Biopharmaceuticals Takes Over BPD II-78
Bharat Biotech Completes Phase I/II Clinical Trials for 116E
Oral Rotavirus Vaccine II-78
Intas Biopharmaceuticals to Commercialize Gefitinib in India II-79
Avesthagen Inks LoI with ShigaMediX II-79
Ranbaxy Signs Collaborative Research Agreement with DBT II-79
Veeda Establishes Global Oncology Contract Research Organization II-80
Avesthagen Signs Framework Agreement with DuBiotech II-80
Biocon Buys Majority Stake in German Company II-80
Monsanto India to Sell Butachlor & Alachlor Businesses to
Sinochem International II-80
Biocon Signs Strategic Partnership Agreement with IATRICa II-81
Intas Pharmaceuticals to Sell Biotechnology Products in GCC II-81

15. FOCUS ON SELECT LEADING PLAYERS II-82
Advanced Enzymes Technologies Ltd. II-82
Ajeet Seeds Ltd. II-82
Anthem BioSciences Pvt. Ltd. II-82
Bharat Biotech International Limited II-83
Bharat Serums and Vaccines Ltd. II-83
Biocon Limited II-84
Syngene International Limited II-85
Dr. Reddys Laboratories Ltd II-85
Ecron Acunova II-86
Eli Lilly and Company (India) Pvt. Ltd. II-86
GlaxoSmithKline Pharmaceuticals Ltd. II-86
Indian Immunologicals Ltd. II-87
Jubilant Life Sciences Limited II-87
Krishidhan Seeds Private Limited II-88
Lambda Therapeutic Research Ltd. II-88
Mahyco II-89
Max Neeman II-89
Monsanto II-89
Novo Nordisk India Pvt. Ltd. II-90
Novozymes South Asia Pvt. Ltd. II-90
Nuziveedu Seeds Pvt. Ltd. II-91
Ocimum Biosolutions Ltd. II-91
Panacea Biotec Ltd. II-92
Piramal Healthcare Limited II-92
Quintiles India II-93
Rasi Seeds (P) Ltd. II-93
Reliance Life Sciences II-94
Serum Institute of India Ltd. II-94
Shantha Biotechnics Limited II-95
SIRO Clinpharm II-95
Strand Life Sciences II-95
Veeda Clinical Research Limited II-96
Vimta Labs Limited II-96

16. MARKET ANALYTICS II-97
Table 14: Indian Recent Past, Current & Future Analysis for
Biotechnology Industry by Sector - Bio-Pharmaceuticals,
Bio-Agriculture, Bio-Industrial, Bioinformatics, and
Bio-Services Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-97

Table 15: Indian Historic Review for Biotechnology Industry by
Sector- Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial,
Bioinformatics, and Bio-Services Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) II-98

Table 16: Indian 15-Year Perspective for Biotechnology
Industry by Sector - Percentage Breakdown of Dollar Sales for
Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial,
Bioinformatics, and Bio-Services Markets for Years 2003, 2011
and 2017 (includes corresponding Graph/Chart) II-99

Table 17: Indian Recent Past, Current & Future Analysis for
Bio-Pharmaceuticals by Segment - Vaccines, Diagnostics,
Therapeutics, and Others Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-100

Table 18: Indian Historic Review for Bio-Pharmaceuticals by
Segment - Vaccines, Diagnostics, Therapeutics, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-101

Table 19: Indian 15-Year Perspective for Bio-Pharmaceuticals
by Segment - Percentage Breakdown of Dollar Sales for
Vaccines, Diagnostics, Therapeutics, and Others Markets for
Years 2003, 2011 and 2017 (includes corresponding Graph/Chart) II-102

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 102 (including Divisions/Subsidiaries - 111)

------------------------------------------
Region/Country Players
------------------------------------------
India 111
------------------------------------------

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos